Breast Cancer Clinical Trial
Official title:
The Recovery of Reaching Movement in Breast Cancer Survivors: Two Different Rehabilitative Protocols in Comparison
This study emphasizes the importance of rehabilitation in breast cancer survivors after mastectomy, even during the course of radiotherapy and chemotherapy, both for good efficacy in reducing pain and for functional recovery of the upper limb. Authors designed a randomized-controlled trial to compare two different rehabilitation protocols: the single rehabilitative treatment (ST) and the group treatment (GT). The study is the first attempt to measure the reaching movement after BC surgery with an optoelectronic evaluation system previously standardized in the neurological field during rehabilitation treatment.
Breast cancer (BC) is the most common cancer in women in the developed world. Surgery and
medical protocols have improved significantly over the last 10 years and this guarantees a
better chance of survival and an improvement in quality of life.
Then, the focus on "what happen after defeating BC" has become current: patients' and
physicians' awareness of the sequelae of BC surgery has increased, especially in the case of
mastectomy or modified radical mastectomy. A large number of these complications, such as
lymphedema or post-treatment pain with or without functional impotence, which contribute to
limitations in daily life activities, can be treated favourably and, in sometimes, resolved
with early rehabilitation protocols. Therefore, it is not only important to start the
rehabilitation process early after surgery, but, also, during the sub-acute phase, choose
appropriate exercise programs to allow recovery in "quantity" and "quality" of the movement
of the operated upper limb (UL). Alterations in muscle activation and reduced shoulder
mobility are common in patients with BC. It is necessary to consider that winged scapula
incidence in BC surgery is 8% and the prevalence decreased during 6 months after surgery. In
particular, patients who developed winged scapula had more shoulder flexion, adduction and
abduction limitation. These findings suggest that, after BC surgery, soft tissues
restrictions obstruct short-term scapula motion.
Reaching movement is a complex multi-articular movement towards a defined point in space and
allows the hand to interact with the environment. Nevertheless, it is not yet investigated
during the rehabilitation process. Moreover, the execution of the UL movements, improves if
the numerous perturbations of the musculoskeletal system, which occur during the execution of
movements, are compensated. Motor synergy's components should modify their action to
influence positively the outcome of motor activity, preventing the mistakes of the individual
components from influencing the overall activity. An important issue is represented by the
redundancy of the degrees of motor freedom. Actions and movements can be performed in
different ways because the functional synergies are able to co-vary, without changing the
result of the action. However, only three spatial dimensions are needed to specify any
position where the hand could be placed. This excess of kinematic degrees of freedom means
that there are multiple arm configurations that correspond to any particular position of the
hand. Thus, improvements in reaching, after BC mastectomy, can be determined, compared to a
different rehabilitation protocol, by comparing the Single rehabilitative Treatment (ST) with
Group Treatment (GT). Authors designed a randomized-controlled trial to check if specific
scapula exercises, included in the ST, could induce changes in the fluidity of the reaching,
called Jerk (primary outcome), decrease shoulder pain and improve the functioning of the
operated upper limb (secondary outcomes).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |